American Society of Clinical Oncology

SHERPA: White

People

  1. Motzer
    Motzer
  2. Scher
    Scher
  3. O'Reilly
    O'Reilly
  4. Saltz
    Saltz
  5. Bajorin
    Bajorin
  6. Kris
    Kris
  7. Hudis
    Hudis
  8. Morris
    Morris
  9. Rosenberg
    Rosenberg
  10. Robson
    Robson

Groups

  1. Department of Medicine (6360)
  2. Solid Tumor Oncology Division (5501)
  3. Survivorship Research (1982)
  4. Genitourinary Oncology Service (1761)
  5. Surgery (1632)
  6. Epidemiology and Biostatistics (1476)
  7. GSK Faculty (1380)
  8. Population Sciences Research Program (1360)
  9. Gastrointestinal Oncology Service (1350)
  10. Hematologic Malignancies, Division of (1273)
Search Within
Formats
  1. Meeting Abstract (6334)
  2. Journal Article (2561)
  3. Editorial (73)
  4. Review (65)
  5. Guidelines (54)
  6. Correspondence (48)
  7. Miscellaneous (4)
  8. Conference Paper (3)
Groups
  1. Department of Medicine (6360)
  2. Solid Tumor Oncology Division (5501)
  3. Survivorship Research (1982)
  4. Genitourinary Oncology Service (1761)
  5. Surgery (1632)
  6. Epidemiology and Biostatistics (1476)

More Groups

People
  1. Robert Motzer (450)
  2. Howard Scher (334)
  3. Eileen O'Reilly (306)
  4. Leonard Saltz (283)
  5. Dean Bajorin (280)
  6. Mark Kris (253)

More People

Years
  1. 2025 (250)
  2. 2024 (554)
  3. 2023 (580)
  4. 2022 (554)
  5. 2021 (504)
  6. 2020 (539)

More Years

Publications
  1. Journal of Clinical Oncology (8678)
  2. JCO Precision Oncology (166)
  3. Journal of Oncology Practice (124)
  4. American Society of Clinical Oncology Educational Book (112)
  5. JCO Clinical Cancer Informatics (53)
  6. JCO Oncology Practice (4)

More Publications

Results (9142)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • INSIGHT: A phase 3, randomized, open-label study of ripretinib vs sunitinib in patients with advanced gastrointestinal stromal tumor previously treated with imatinib with KIT exon 11 + 17/18 mutations
    Meeting Abstract

    Heinrich, M. C.; Blay, J. V.; Chi, P.; Jones, R. L.; Serrano, C.; Somaiah, N.; Gelderblom, H.; Zalcberg, J. R.; Reichmann, W.; Sprott, K.; more...
    Journal of Clinical Oncology (2025)

    Fulltext@MSK | Save
  • How racialized approaches to opioid use disorder and opioid misuse management hamper pharmacoequity for cancer pain
    Editorial

    Jones, K. E.; Liou, K. T.; Ashare, R. L.; Worster, B.; Yeager, K. A.; Merlin, J.; Meghani, S. H.
    Journal of Clinical Oncology (2025)

    Fulltext@MSK | Save
  • Menin inhibition with revumenib for KMT2A -rearranged relapsed or refractory acute leukemia (AUGMENT-101)
    Journal Article

    Issa, G. C.; Aldoss, I.; Thirman, M. J.; DiPersio, J.; Arellano, M.; Blachly, J. S.; Mannis, G. N.; Perl, A.; Dickens, D. S.; McMahon, C. M.; more...
    Journal of Clinical Oncology (2025)

    Fulltext@MSK | Save
  • A phase I trial of intraperitoneal (IP) mesothelin (MSLN)-targeted CAR T-cell therapy in patients with MSLN-positive esophagogastric cancer (EGC) with peritoneal carcinomatosis
    Meeting Abstract

    Choo, J.; Saini, J.; Gonzalez-Aguirre, A.; Dahi, P.; Hieronymi, S.; Fernstedt, S.; Tan, K. S.; Adusumilli, P. S.; Ku, G. Y.
    Journal of Clinical Oncology (2025)

    Fulltext@MSK | Save
  • A phase II study of agenT-797 (invariant natural killer T-cells), botensilimab (Fc-enhanced CTLA-4 inhibitor) and balstilimab (anti-PD-1) in patients with advanced, refractory gastroesophageal adenocarcinoma
    Meeting Abstract

    Cytryn, S. L.; Maron, S. B.; Janjigian, Y. Y.
    Journal of Clinical Oncology (2025)

    Fulltext@MSK | Save
  • Alliance A022101/NRG-GI009: A pragmatic randomized phase III trial evaluating total ablative therapy for patients with limited metastatic colorectal cancer—Evaluating radiation, ablation, and surgery (ERASur)
    Meeting Abstract

    Romesser, P. B.; Miller, E. D.; Shi, Q.; Dixon, J. G.; Gholami, S.; White, S. B.; Wu, C.; Goulet, C. C.; Jee, K. W.; Wright, C. L.; more...
    Journal of Clinical Oncology (2025)

    Fulltext@MSK | Save
  • Phase 1/2 study of FOG-001, a first-in-class direct β-catenin:TCF inhibitor, in patients with colorectal cancer, hepatocellular carcinoma, and other locally advanced or metastatic solid tumors
    Meeting Abstract

    Papadopoulos, K. P.; Cecchini, M.; Khushman, M. M.; Pelster, M.; Rodon Ahnert, J.; Kummar, S.; Yaeger, R.; Sharma, S.; Wells, A. L.; Garofalo, A.; more...
    Journal of Clinical Oncology (2025)

    Fulltext@MSK | Save
  • CLARITY-Gastric 01: A randomized phase 3 study of AZD0901, a Claudin18.2 (CLDN18.2)-targeted antibody-drug conjugate, in second- or later-line (2L+) advanced gastric or gastroesophageal junction cancer (GC/GEJC)
    Meeting Abstract

    Janjigian, Y. Y.; Shitara, K.; Elimova, E.; Zhang, J.; Chen, M. H.; Smyth, E. C.; Lee, J.; Miao, R.; Liu, S.; Holmblad, M.; more...
    Journal of Clinical Oncology (2025)

    Fulltext@MSK | Save
  • Valemetostat and trastuzumab deruxtecan (T-DXd) in previously treated advanced or metastatic human epidermal growth factor receptor 2 (HER2)-positive gastric cancer or gastro-esophageal junction (GEJ) adenocarcinoma
    Meeting Abstract

    Shitara, K.; Enzinger, P. C.; Mohapatra, A.; Janjigian, Y. Y.
    Journal of Clinical Oncology (2025)

    Fulltext@MSK | Save
  • KEYMAKER-U06: Phase 1/2 umbrella platform study of TROP2 antibody-drug conjugate sacituzumab tirumotecan plus pembrolizumab plus chemotherapy (substudy 06C) and sacituzumab tirumotecan plus paclitaxel (substudy 06D) in gastroesophageal adenocarcinoma
    Meeting Abstract

    Oh, D. Y.; Xu, J.; Tabernero, J.; Van Cutsem, E.; He, T.; Bhaumik, S.; Bhagia, P.; Janjigian, Y. Y.
    Journal of Clinical Oncology (2025)

    Fulltext@MSK | Save